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Table. Incremental and attributable hospital costs associated with
peri-procedural complications of TAVR
Complication
Incremental
Cost
(per event)
Attributable Cost (per patient)
Overall
(n ¼ 506)
IF group
(n ¼ 397)
Non-IF
group
(n ¼ 109)
Death $10,176 $519 $509 $560
Major Stroke $20,769 $623 $312 $1,724
AKI Stage 3 $29,587 $473 $444 $533
Bleeding
Life-threatening $15,845 $2,123 $1,870 $3,058
Major $7,130 $1,932 $1,740 $2,617
Arrhythmia $7,740 $1,618 $1,440 $2,276
Perm. Pacemaker Implant $13,861 $2,523 $2,717 $1,774
Repeat TAVR $116,732 $934 $1,167 –
Total Cost of Complications $10,745 $10,197 $12,541
R2 of model ¼ 0.36
IF¼Iliofemoral access; Non-IF¼Non-iliofemoral access; AKI ¼ acute kidney injury
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Background: Only few data are available on the impact of mixed aortic stenosis
(MAS) on clinical outcomes and post-procedural aortic regurgitation (PPAR) after
transcatheter aortic valve implantation (TAVI). The aim of this study was to assess the
impact of MAS on PPAR and clinical outcomes after TAVI.
Methods: Data from a multicenter registry were retrospectively analysed. Outcomes
were compared between patients with pure aortic stenosis (PAS; associated AR
< 1+/3+) and MAS (associated AR  1+/3+). Study objectives were PPAR incidence
and Valve Academic Research Consortium 2 (VARC-2) outcomes at long-term
follow-up.
Results: In total, 1091 patients were included: 432 (39.5%) with MAS and 659
(60.4%) with PAS. At 30 days, there were no differences in all-cause (6.4% vs. 6.3%;
p ¼ 0.930) and cardiovascular mortality (5.5% vs. 4.2%; p ¼ 0.315), however a
greater incidence of major bleeding (23% vs. 16.5%; p ¼ 0.011), spontaneous
myocardial infarction (2% vs. 0.3%; p ¼ 0.019) and PPAR  1+/3+ (43% vs. 27%;
p < 0.001) was observed in patients with MAS. Of note, MAS was an independent
predictor of PPAR  1+/3+ at multivariable analysis. At a median follow-up period of
421 days (IQR 252 – 710), patients with MAS had a higher all-cause (30% vs. 24%;
p ¼ 0.047) and cardiovascular mortality (17% vs. 12%; p ¼ 0.023). Conversely, in
patients that developed PPAR  2+/3+ the presence of baseline MAS was associated
with a trend of lower long-term all-cause and cardiovascular mortality (46% vs. 73%,
p ¼ 0.188 and 17% vs. 50%, p ¼ 0.095).
Conclusions: MAS was associated with a higher PPAR incidence and increased all-
cause and cardiovascular mortality when compared to patients with PAS. However, in
patients who developed PPAR  2+/3+, baseline MAS trended to be associated with
improved long-term survival.
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Background: In patients (pts) with severe aortic stenosis, transcatheter aortic valve
replacement (TAVR) improves survival compared with medical therapy but is asso-
ciated with higher costs. Prior studies have shown that peri-procedural complications
have a sizeable effect on cost in pts treated with a balloon-expandable prosthesis, but
no studies to date have examined the impact of complications on costs in pts treated
with a self-expanding prosthesis.B200 JACC Vol 64/11/Suppl B j SepMethods: Using hospital cost data from 506 pts enrolled in the CoreValve US Pivotal
Extreme Risk study, we developed multivariable models to estimate the incremental
cost associated with speciﬁc complications of TAVR. Complications were deﬁned
according to the VARC-1 criteria and adjudicated by an independent events com-
mittee. Attributable costs were calculated by multiplying the incremental cost of each
event by its frequency.
Results: Mean cost for the initial hospitalization (including physician fees and cost of
the valve) was $73,701 + 26,981. Overall, complications accounted for $10,197 per pt in
the ilio-femoral access (IF) cohort and $12,541 per pt in the non-IF access cohort (25%
and 27% of non-implant related costs, respectively). For IF pts, permanent pacemaker
implantation and bleeding complications accounted for the largest attributable cost,
whereas bleeding complications and arrhythmias contributed most in non-IF pts.
Conclusions: In this initial US experience with the Medtronic CoreValve device, peri-
procedural complications accounted for up to 27% of non-implant related hospital
costs. Both the absolute and relative cost increases were greater among pts treated via
a non-IF approach. In the future, avoidance of complications should improve the cost-
effectiveness of TAVR in inoperable pts treated with a self-expanding prosthesis –
particularly for pts unsuitable for IF access.TCT-686
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Background: Aortic stenosis (AS) induces adaptive left ventricular (LV) remodeling,
with some geometric patterns associated with increased morbidity and mortality after
surgical aortic valve replacement (AVR). Whether the geometric pattern of LV
remodeling at baseline impacts outcomes after transcatheter AVR (TAVR) remains
unknown.
Methods: The PARTNER randomized trial and continued access registry included
high-risk (n¼2,184) and inoperable (n¼508) patients with symptomatic severe AS.
Using relative wall thickness cut points for concentric geometry (>0.42) and sex-
speciﬁc LV mass index thresholds for severe LV hypertrophy (>149 g/m2 for men
and >122 g/m2 for women) on baseline echocardiograms, patients were stratiﬁed into
four LV geometric patterns: normal geometry, concentric remodeling (cLVR),
concentric hypertrophy (cLVH), and eccentric hypertrophy (eLVH). Clinical out-
comes associated with each geometric pattern were assessed.
Results: Of 2,692 patients (mean age, 85 years; 52% male) with mean LV ejection
fraction 5213%, normal geometry, cLVR, cLVH, and eLVH were present in 13, 37,
40, and 10%, respectively. Rates of all-cause and cardiac death were comparable
across groups at 30 days. Patients with normal LV geometry demonstrated the worst
survival at 6 months (20.7% vs 14.6% with cLVR; P¼0.008) and 1 year (26.2% vstember 13–17, 2014 j TCT Abstracts/Valvular disease - Aortic: TAVR
